Last updated: November 2026
Australian Shepherd MDR1, explained with care
The Australian Shepherd is brilliant, devoted, and always ready for one more run, and nothing about this gene changes that. What it changes is how the brain handles certain common medicines. This guide explains what the MDR1 gene change is, how common it is in each tested population, which drugs need care, why monthly heartworm prevention still belongs in your routine, and how one simple DNA test gives every vet who treats your Aussie the answer for life.
The quick answer
There is no single honest number, because the studies count different things, and this page keeps them labeled and separate. In the peer reviewed survey by Neff et al. 2004, the mutant allele made up 16.6% of gene copies in 178 Australian Shepherds, and 31.5% of those dogs carried at least one copy: 1.7% carried two copies and 29.8% carried one. The Washington State University testing program puts its approximate frequency at about 50% of tested Australian Shepherds carrying at least one copy, a share of dogs figure from its own testing population, labeled approximate on its own page. Only one drug is an outright avoid on the current Washington State University list: loperamide, the anti-diarrhea drug sold as Imodium. Monthly heartworm prevention at label doses is considered safe, even for dogs with two copies. A university laboratory test costs $58 at UC Davis or $70 at Washington State University, once in a dog's life. Our Australian Shepherd breed guide covers the rest of this breed's story, the eye checks and active-dog years that fill most of an Aussie's vet file.
Sources: Neff et al. 2004, Proceedings of the National Academy of Sciences (PNAS), breed distribution study of more than 4,000 purebred dogs; Washington State University Program in Individualized Medicine, dog breeds commonly affected by the MDR1 mutation (approximate frequency table); Washington State University WADDL problem medications list for dogs.
What MDR1 actually is
Every dog has the MDR1 gene, also called the ABCB1 gene. It builds a protein called P-glycoprotein, which works as a pump at the blood-brain barrier: it limits how much of certain drugs reach the brain, and it helps the body clear many drugs out. Washington State University and the UC Davis Veterinary Genetics Laboratory describe the same job the same way, a drug transporter that keeps substances from building up in the brain.
The change itself is small and exact. A deletion of 4 base pairs in the gene, written ABCB1-1Delta and also called mdr1-1Delta or nt230(del4), shifts the reading frame and produces a severely truncated protein, under 10% of its normal length, that cannot do the pumping job (Neff et al. 2004). Dr. Katrina Mealey and colleagues first identified this mutation in Collies in 2001. Without a working pump, listed drugs that should have been kept out of the brain build up there instead, and a normal dose can become a dangerous one.
Inheritance is autosomal incomplete dominance with incomplete penetrance, in UC Davis's wording. In plain words: one copy can matter, two copies matter most, and carrying a copy is not an illness. A healthy Aussie with two copies looks and acts completely normal until a listed drug is given. Because every animal has the gene, Washington State University asks owners not to describe a result as simply positive or negative. Results are genotypes: normal/normal, mutant/normal, or mutant/mutant.
How common it is, honestly
Four research datasets and one testing program table answer this question, and they do not measure the same thing. An allele frequency counts gene copies in a sample. A genotype share counts dogs. This page prints each dataset with its population and its method, and never blends them into one figure.
Neff et al. 2004 (PNAS). In 178 Australian Shepherds drawn from a Veterinary Genetics Laboratory repository and volunteer breeders and owners, the mutant allele frequency was 16.6%. The genotypes were 1.7% mutant/mutant, 29.8% mutant/normal, and 68.5% normal/normal. Adding the first two gives the share who carried at least one copy in that sample: 31.5% of dogs. That last figure is arithmetic from the published table, labeled as such.
Mealey and Meurs 2008 (JAVMA). In 5,368 North American dogs whose buccal swab samples were submitted for ABCB1 genotyping between May 2004 and September 2007, the reported mutant allele frequency in Australian Shepherds was 29%, as summarized in the curated OMIA record for this variant. This was a genotyping caseload, meaning dogs whose owners and vets chose to test, not a random sample of the breed.
Gramer et al. 2011. In Australian Shepherds in a German tested population, the mutant allele frequency was 22%, again as summarized in the OMIA record. The Australian Shepherd sample size was not captured in that summary, so this page prints no denominator for it.
Lerdkrai et al. 2021 (Veterinary World, Thailand). In 39 Australian Shepherds tested between February 2018 and December 2020, the mutant allele frequency was 12.8%. The genotypes were 29 of 39 dogs normal/normal (74.4%), 10 of 39 mutant/normal (25.6%), and 0 of 39 mutant/mutant. The authors note that about two-thirds of these dogs came from two breeding kennels and about 10 descended from the same parental pair, so a sample this small can be moved by relatedness.
Washington State University testing program. The university's approximate frequency table puts Australian Shepherds at 50%, with no denominator or method printed on the page. Read as what it is, a share of tested dogs carrying at least one copy in that program's population, it sits comfortably beside the allele studies: under random mating, an allele frequency near 29% corresponds to roughly half of dogs carrying at least one copy. That comparison is arithmetic, not a measurement, and this page labels it that way.
The honest headline is this: in the studies that count gene copies, the mutant allele runs from about 13% to about 29% in Australian Shepherds depending on the population tested, and the Washington State University program puts roughly half of tested Aussies as carrying at least one copy. The only way to know your own dog is to test your own dog.
Sources: Neff et al. 2004, PNAS Table 1; Mealey and Meurs 2008, JAVMA, breed distribution among 5,368 genotyped dogs, with the breed allele figure as summarized in OMIA:001402-9615; Gramer et al. 2011, German tested population, via OMIA:001402-9615; Lerdkrai et al. 2021, Veterinary World; Washington State University Program in Individualized Medicine, approximate frequency table.
The drugs that need care
Washington State University's problem medications list is the working list on this page. The university states that it is kept current and includes only drugs that have undergone peer reviewed publication, and that dosing questions beyond the table go to MDR1Caddie, its pharmacology consultation service run with Dr. Mealey. Cornell, UC Davis, PetMD, and VCA Animal Hospitals corroborate the core of the list.
| Drug or group | What the Washington State University list says |
|---|---|
| Loperamide (Imodium) | Avoid in all dogs with the mutation. At the doses used to treat diarrhea, it causes neurological toxicity in dogs with the mutation. |
| Acepromazine, apomorphine, butorphanol (Torbugesic), cyclosporine (Atopica), grapiprant (Galliprant), maropitant (Cerenia), ondansetron, and chemotherapy drugs (doxorubicin, vinblastine, vincristine, vinorelbine) | Contact MDR1Caddie for dosing recommendations. This is a dose adjustment or alternative drug conversation with your vet, not an automatic ban. |
| Ivermectin (Heartgard Plus), milbemycin (Interceptor, Interceptor Plus), moxidectin (ProHeart, Simparica Trio, Nexgard Plus, Advantage Multi), selamectin (Revolution) | Tested by the manufacturer with no adverse effects observed. The FDA determined these products are safe for dogs with the mutation when used at label doses. |
| Afoxolaner (Nexgard), fluralaner (Bravecto), lotilaner (Credelio), sarolaner (Simparica) | Tested by the manufacturer with no adverse effects observed, and no increased risk stated for dogs with the mutation. |
One careful boundary: a drug that is not on this list has not been cleared by it, and a drug named on other websites is not added here unless a named source in this guide supports it. When your Aussie needs any new medicine, the genotype result in the vet record is what turns this table into a personal plan.
Heartworm prevention is still safe
This is the misunderstanding most likely to harm an Aussie, so it gets its own section. The dose is the whole story. Mealey 2008, in Veterinary Parasitology, states that at the manufacturer's recommended dose, all FDA-approved heartworm preventive products marketed in the United States are safe, even for dogs with the mutant/mutant genotype. Cornell states the same rule in owner language: heartworm preventives are still safe at low, FDA-approved dosages, while ivermectin can cause toxicity at high dosages. VCA Animal Hospitals agrees.
The standard monthly heartworm prevention dose of ivermectin is 6 micrograms per kilogram, as printed in the Veterinary Information Network formulary summary and the Petco ivermectin monograph. The danger lives at the other end of the scale: high-dose ivermectin, such as mange treatment doses and livestock formulations made for cattle and horses, which are many times the heartworm dose. Never give a cattle or horse ivermectin product to a dog. And never stop or skip heartworm prevention on your own out of fear of this gene: that trades a managed, label-tested risk for heartworm disease itself. Talk to your vet about product choice, with the genotype in hand.
What a reaction looks like
The mutation itself causes no day-to-day symptoms. Signs follow a dose. Cornell's Riney Canine Health Center lists the most common signs of drug toxicity in dogs with MDR1 drug sensitivity as vomiting, weakness, uncoordinated movement, tremors, seizures, blindness, and death. UC Davis adds excess salivation, slow heart rate, dilated pupils, and respiratory arrest, and the OMIA clinical summary notes that dilated pupils may be the most sensitive sign. There is no cure or antidote: a dog having a reaction is treated with supportive care based on its symptoms (Cornell).
- Emergency signs, same day, no waiting: wobbling or uncoordinated movement, tremors, drooling, dilated pupils, blindness, collapse, or unusual sleepiness after any new medication. Call your vet or an emergency hospital now, and take the medication packaging with you.
This guide cannot diagnose your dog. If you are seeing emergency signs, please call your vet or an emergency hospital now.
Testing your Aussie
The test is simple. Both university laboratories accept a cheek swab collected at home with a DNA brush, or a whole blood sample collected at the clinic, and both use PCR to look for the same 4 base pair deletion. Washington State University provides sampling kits free of charge on order.
| Result | What it means |
|---|---|
| Normal/normal | No copies of the deletion. Expected not to have multidrug sensitivity caused by this variant, and cannot pass the variant to puppies (UC Davis). |
| Mutant/normal | One copy. May show multidrug sensitivity, typically milder than with two copies, and passes the variant to about 50% of puppies on average (UC Davis). Cornell agrees that a dog with one copy can still react, generally less severely. |
| Mutant/mutant | Two copies. Likely to show severe signs of multidrug sensitivity with listed drugs, in UC Davis's wording even at low doses for some of them. |
One honesty note this page keeps: the standard test detects the well-known 4 base pair deletion only. Drug sensitivity can also arise from other, rarer ABCB1 variants, and from drug combinations that inhibit P-glycoprotein in any dog, so a normal/normal result is not a promise that every drug is safe for that dog (UC Davis).
The two university laboratories print their own prices, and this page prints both with their labels rather than blending them. Washington State University charges $70 for medical diagnostic quality MDR1 genotyping with pharmacology consulting included, and its test catalog gives a turnaround of 2 to 7 business days. UC Davis charges $58 for a single test per animal, with a $5 discount on 3 or more dogs, or $27 as an additional health test on the same animal, and gives a turnaround of at least 15 business days. Any collection fee at your clinic, or shipping, is separate from these laboratory prices.
Living with a result
A result only protects a dog if every vet who treats the dog sees it. UC Davis states that results should be shared with the dog's veterinarian before pharmacological treatments, and PetMD gives owners the same step: if you test on your own, give your vet a copy of the results for the medical record. Cornell's standing rule belongs in the same paragraph: speak with your veterinarian before changing any drug dosages or stopping a drug.
A result changes prescribing; it does not end treatment. Cornell puts it plainly: with proper consideration of drug interactions and dosages, dogs with this sensitivity can live normal lives without incident, because vets can avoid a listed drug, lower its dose, or choose an alternative. Washington State University built MDR1Caddie for exactly this moment: Dr. Mealey and her team work with the owner and the veterinarian on alternative medications and doses when a pet needs a drug known to cause adverse reactions.
One careful breeding note, and only one. Because this sensitivity can be managed once it is identified, Cornell notes that eliminating every dog with the variant from a breeding program is not recommended. UC Davis prints the mating arithmetic: two mutant/normal parents produce, on average, 25% of puppies with two copies and 50% with one copy. Testing before breeding is information for breeder and buyer conversations, never a verdict on any individual dog's worth.
A Collie family story
The history explains why this gene clusters in herding breeds. Neff et al. 2004 found the same mutant version of the gene, identical by descent, across the affected breeds, and concluded that all dogs carrying it are descendants of a dog that lived in Great Britain before the genetic isolation of breeds by registry, around 1873, when formally recognized breeds emerged from an admixed population of working sheepdogs. Australian Shepherds were developed in the American West, but they share ancestry with Collies, which is why a Collie-lineage mutation lives in this breed at all. Dr. Mealey's team at Washington State University discovered the mutation in dogs and cats and first made the test commercially available.
Family members sit at very different points on the same datasets, and each figure keeps its breed name attached. Collies sit highest: the Washington State University table puts tested Collies at about 70% carrying at least one copy. Border Collies sit far lower: under 5% on the same Washington State University table, and a mutant allele frequency of 1% in both the US genotyping summary and the German study summarized by OMIA. Our Border Collie breed guide tells that dog's version of this story with its own figures. This section is history and context: it explains the pattern, and it changes nothing about testing or prescribing for an individual dog.
How insurance fits this breed
Start with what the test is, in coverage terms. It is a one-time preventive genetic screen on a healthy dog, not treatment of an illness or injury, and accident and illness plans are built to pay for illness and injury treatment, with preventive care generally excluded unless a wellness add-on is bought. One carrier's exclusion list, as summarized from its policy documents in a 2026 policy review, names DNA testing among its excluded items. So the honest wording is plan dependent: testing is generally not reimbursed, and your own sample policy is the document that decides. No page can promise an outcome for an individual plan, in either direction.
What insurance does fit is the emergency itself. Emergency treatment of an actual drug reaction is illness and emergency care, the category accident and illness coverage exists for, subject to the policy's terms, waiting periods, and pre-existing condition rules. Timing matters here in a specific way: enroll before any drug reaction, neurological episode, or related treatment is in the record, because a documented reaction before enrollment can follow the dog as pre-existing history. Our pre-existing conditions guide carries the mechanics.
For context, the national average premium for dogs is $62.44 per month (NAPHIA, 2024 data), exactly as our breed guide frames it, and there is no trustworthy Australian Shepherd specific premium to quote here. The value story is two layers, and neither replaces the other. A $58 to $70 university laboratory test, done once in a dog's life, buys a lifetime of safer prescribing for less than one month of average premiums: that is protection an owner can give directly, with love. Insurance is the second layer, standing behind the emergency you hope never happens and behind the rest of this breed's story, the eye checks and active-dog injuries our breed guide describes. Use our pet insurance cost estimator for typical premiums, and our lifetime cost projector to set one large vet bill beside years of premiums. Our Dachshund IVDD guide, Golden Retriever cancer guide, and German Shepherd hip dysplasia guide are the sibling deep-dives for breeds whose signature risks sit in the spine, in cancer, and in the hips.
Frequently asked questions
What is MDR1 in Australian Shepherds?
It is a change in the ABCB1 gene, also called the MDR1 gene, which builds P-glycoprotein, the pump that keeps certain drugs out of the brain. A deletion of 4 base pairs leaves the pump severely truncated and unable to do that job, so listed drugs can build up in the brain at normal doses. Carrying the change is not an illness: a dog with two copies looks and acts completely normal until a listed drug is given.
How common is the MDR1 mutation in Australian Shepherds?
The studies count different things and are never blended on this page. Neff et al. 2004 found a mutant allele frequency of 16.6% in 178 Australian Shepherds, with 31.5% of dogs carrying at least one copy. Mealey and Meurs 2008 reported a 29% allele frequency in a North American genotyping caseload of 5,368 dogs. The Washington State University testing program puts its approximate frequency at about 50% of tested Australian Shepherds carrying at least one copy. Only a test answers for an individual dog.
Is heartworm prevention safe for a dog with the MDR1 mutation?
Yes, at label doses. Mealey 2008 states that at the manufacturer recommended dose, all FDA-approved heartworm preventive products marketed in the United States are safe, even for dogs with two copies of the mutation, and Washington State University and Cornell state the same rule. High doses are the danger, including mange treatment doses and livestock formulations. Never stop prevention on your own; talk to your vet about product choice.
Which drugs should an Australian Shepherd with the mutation avoid?
Loperamide (Imodium) is the one outright avoid on the Washington State University problem medications list: at diarrhea doses it causes neurological toxicity in dogs with the mutation. A second group is a dosing conversation, not a ban: acepromazine, apomorphine, butorphanol, cyclosporine, grapiprant, maropitant, ondansetron, and chemotherapy drugs including doxorubicin, vinblastine, vincristine, and vinorelbine, where the university routes dosing questions to its MDR1Caddie service.
How do I test my Australian Shepherd for MDR1, and what does it cost?
With a cheek swab collected at home or a blood sample at the clinic, tested by PCR for the 4 base pair deletion. Washington State University charges $70 with pharmacology consulting included and a catalog turnaround of 2 to 7 business days. UC Davis charges $58 for a single test, with a turnaround of at least 15 business days. Results come back as normal/normal, mutant/normal, or mutant/mutant, and the result should be shared with every vet who treats your dog.
Does pet insurance cover MDR1 testing or a drug reaction?
Testing is a one-time preventive screen, and preventive and DNA testing are generally not reimbursed under accident and illness plans unless a wellness add-on covers them, so read your own sample policy: the answer is plan dependent. Emergency treatment of an actual drug reaction is illness and emergency care, the category those plans exist for, subject to the policy terms, waiting periods, and pre-existing condition rules, which is why enrolling before any reaction is recorded matters.